Menu Search
Equities

Compugroup Medical Se

COP1N:MEX

Compugroup Medical Se

Actions
  • Price (MXN)1,396.80
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Jan 18 2022 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Compugroup Medical Se had net income fall -37.45% from 73.41m to 45.92m despite a 5.13% increase in revenues from 1.13bn to 1.19bn. An increase in the cost of goods sold as a percentage of sales from 63.58% to 65.09% was a component in the falling net income despite rising revenues.
Gross margin33.03%
Net profit margin2.20%
Operating margin7.43%
Return on assets1.31%
Return on equity3.77%
Return on investment1.60%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Compugroup Medical Se fell by 26.06m. However, the company earned 179.53m from its operations for a Cash Flow Margin of 15.12%. In addition the company used 124.33m on investing activities and also paid 80.69m in financing cash flows.
Cash flow per share2.76
Price/Cash flow per share5.25
Book value per share12.26
Tangible book value per share-13.70
More ▼

Balance sheet in EURView more

Compugroup Medical Se has a Debt to Total Capital ratio of 57.28%, a lower figure than the previous year's 103.38%.
Current ratio1.03
Quick ratio0.9826
Total debt/total equity1.34
Total debt/total capital0.5728
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)1.04%
Div growth rate (5 year)14.87%
Payout ratio (TTM)207.56%
EPS growth(5 years)-14.83
EPS (TTM) vs
TTM 1 year ago		-66.96
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.